INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders on June 29, 2011, in Marseilles, France.

Transparency directive : regulatory news

26/05/2011 17:45

PRESS RELEASE

      INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON
                      JUNE 29, 2011, IN MARSEILLES, FRANCE

Marseilles, France, May 26, 2011

Innate Pharma (Euronext Paris: FR0010331421 - IPH) will hold its Annual
General Meeting of Shareholders ("AGM") on June 29, 2011, at 9:30 am in its
headquarters, 117 avenue de Luminy, F-13009 Marseille.

The Notice of Meeting of this Shareholders' Meeting was published on May 25,
2011, in the French official legal bulletin ("BALO"). It includes the agenda,
the proposed resolutions as well as instructions to participate and vote in
this Meeting. It is also available on the Company's website, in the investors'
room.

All documentation regarding this AGM will be made available to shareholders in
accordance with existing regulations and will be available on the Company's
website on June 8, 2011.

Precision regarding the AGM:

Only shareholders having registered their shares at least three business days
prior to the date of the AGM, by midnight Paris time, will be able to attend.

Shareholders holding "au porteur" (bearer) shares will need to obtain an
"attestation de participation" (certificate of shareholding) from their
brokers. This "attestation de participation" must be attached to the proxy
form or to the appropriate voting form if shareholders wish to designate a
proxy or vote by mail. The "attestation de participation" may replace the
admission card for shareholders wishing to attend the AGM in person.

Written questions from shareholders must be received from the day of the
publication of the official convocation to the AGM up until four business days
prior to the AGM (by registered letter, addressed to the registered office, or
by e-mail to investors@innate-pharma.com).

Shareholders may obtain the legal documentation in preparation of the AGM (as
described in article R. 225-83 of the French "Code de Commerce") by sending a
request:

* by regular mail to Innate Pharma, Shareholders Services, 117 avenue de
  Luminy, BP 30191, F-13009 Marseilles, France or

* by e-mail to investors@innate-pharma.com

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its most advanced drug-candidate is IPH 2101, an anti-KIR monoclonal
antibody potentiating NK cells activation currently in Phase II clinical
trials in hematologic cancers. Two of its antibody programs in chronic
inflammation are out-licensed to Novo Nordisk A/S.

Innate Pharma's key expertise is in immunopharmacology and antibody
technology. The Company has implemented in-house a large panel of molecular
and cellular assays and in vivo models for assessing the pharmacodynamics and
pharmacotoxicology of drug candidates. In addition, Innate Pharma has access
to a very large set of unique research tools in cellular immunology through
its worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006,
Innate Pharma is based in Marseilles, France, and had 85 employees as at
March 31, 2011.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code       FR0010331421
Ticker code     IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                      Alize Public Relations
Laure-Hélène Mercier               Caroline Carmagnol
Director, Investor Relations       Phone: +33 (0)1 42 68 86 43
Phone: +33 (0)4 30 30 30 87        Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com        caroline@alizerp.com

IPH_AGM 2011

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders on June 29, 2011, in Marseilles, France.

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories